Company
Island Pharmaceuticals Ltd
ASX:ILA
Island Pharmaceuticals is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. The company has a lead asset – ISLA-101 - that was initially developed by its wholly owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.
30 stories · page 2 of 2
Island Pharmaceuticals could see a re-rating on positive Phase 2a results in H2CY23: MST Access
MST Access has retained Island Pharmaceuticals’ valuation of 63 cents per share (current share price: 18 cents)